Moderna, Inc. $MRNA Shares Acquired by Fifth Third Bancorp

Fifth Third Bancorp increased its position in shares of Moderna, Inc. (NASDAQ:MRNA) by 48.3% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 20,980 shares of the company’s stock after acquiring an additional 6,830 shares during the quarter. Fifth Third Bancorp’s holdings in Moderna were worth $579,000 as of its most recent SEC filing.

A number of other large investors have also made changes to their positions in MRNA. S Bank Fund Management Ltd acquired a new position in Moderna in the 1st quarter valued at approximately $25,000. SVB Wealth LLC acquired a new position in Moderna in the 1st quarter valued at approximately $28,000. CX Institutional increased its stake in Moderna by 1,129.8% in the 2nd quarter. CX Institutional now owns 1,033 shares of the company’s stock valued at $29,000 after buying an additional 949 shares during the period. Costello Asset Management INC acquired a new position in Moderna in the 1st quarter valued at approximately $30,000. Finally, Sentry Investment Management LLC acquired a new position in Moderna in the 1st quarter valued at approximately $31,000. Institutional investors and hedge funds own 75.33% of the company’s stock.

Moderna Stock Up 3.4%

NASDAQ:MRNA opened at $25.33 on Tuesday. Moderna, Inc. has a 12-month low of $23.15 and a 12-month high of $67.96. The firm has a market capitalization of $9.86 billion, a PE ratio of -3.36 and a beta of 1.93. The firm has a 50-day moving average price of $26.80 and a 200 day moving average price of $27.50.

Moderna (NASDAQ:MRNA) last announced its quarterly earnings results on Friday, August 1st. The company reported ($2.13) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.99) by $0.86. Moderna had a negative net margin of 94.31% and a negative return on equity of 25.96%. The firm had revenue of $142.00 million during the quarter, compared to the consensus estimate of $116.26 million. During the same period last year, the firm posted ($3.33) EPS. The firm’s quarterly revenue was down 41.1% on a year-over-year basis. Moderna has set its FY 2025 guidance at EPS. On average, research analysts expect that Moderna, Inc. will post -9.61 EPS for the current year.

Analyst Upgrades and Downgrades

MRNA has been the topic of several research reports. JPMorgan Chase & Co. set a $26.00 price objective on shares of Moderna in a research note on Friday, August 1st. Leerink Partners lowered their target price on shares of Moderna from $18.00 to $15.00 and set an “underperform” rating on the stock in a research report on Friday, August 22nd. Citigroup began coverage on Moderna in a research report on Friday, August 1st. They issued a “neutral” rating and a $40.00 price target for the company. Bank of America reduced their price target on Moderna from $26.00 to $25.00 and set an “underperform” rating for the company in a research report on Tuesday, July 22nd. Finally, Wells Fargo & Company reaffirmed an “equal weight” rating on shares of Moderna in a research report on Sunday, July 13th. One investment analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, fourteen have given a Hold rating and four have assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus price target of $41.81.

Moderna Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.